Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rezolute, Inc.RZLT · Entity 1990 | Chief Scientific Officer | July 31, 2019 | September 16, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rezolute, Inc.
Report date July 31, 2019 · Filed September 16, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2029-07-31 | Direct | 3,500,000 |
Reported balance
After 2019-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-31 · Grant · Acquired 3,500,000 · Balance 3,500,000 F1: 587,500 of the options is fully exercisable as of the date of grant. Vesting of 1,762,500 options will occur in thirty-six equal installments beginning on the first day of each month thereafter, such grant vested in full after 3 years. The remaining 1,150,000 options vest equally over a 36-month period following certain performance and market price criteria. Such remaining options will not necessarily vest or convert into non-derivative securities to be beneficially owned by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: 587,500 of the options is fully exercisable as of the date of grant. Vesting of 1,762,500 options will occur in thirty-six equal installments beginning on the first day of each month thereafter, such grant vested in full after 3 years. The remaining 1,150,000 options vest equally over a 36-month period following certain performance and market price criteria. Such remaining options will not necessarily vest or convert into non-derivative securities to be beneficially owned by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2019 Filed Sep 16, 2019 17:14 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantStock Option (right to buy) · Derivative | 3,500,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001567619-19-018368 · doc1.xml · derivative · entry 1 Mantripragada Sankaram · CIK 0001405632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500,000 Underlying: Common Stock · 3,500,000 shares Expires 2029-07-31 F1 · derivative.exercise_date: 587,500 of the options is fully exercisable as of the date of grant. Vesting of 1,762,500 options will occur in thirty-six equal installments beginning on the first day of each month thereafter, such grant vested in full after 3 years. The remaining 1,150,000 options vest equally over a 36-month period following certain performance and market price criteria. Such remaining options will not necessarily vest or convert into non-derivative securities to be beneficially owned by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.